NCT04695405View on ClinicalTrials.gov

Pharmacogenetics Associated With IV Ketamine

CompletedOBSERVATIONAL
Enrollment

85

Participants

Timeline

Start Date

January 21, 2021

Primary Completion Date

July 2, 2021

Study Completion Date

July 2, 2021

Conditions
Treatment Resistant Depression
Interventions
GENETIC

Saliva Genetic Samples

Patients will provide two saliva swabs containing genetic materials.

Trial Locations (1)

L5C 4E7

Canadian Rapid Treatment Centre of Excellence, Mississauga

All Listed Sponsors
lead

Brain and Cognition Discovery Foundation

OTHER

NCT04695405 - Pharmacogenetics Associated With IV Ketamine | Biotech Hunter | Biotech Hunter